Cell Metabolism
Volume 24, Issue 6, 13 December 2016, Pages 795-806
Journal home page for Cell Metabolism

Article
Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice

https://doi.org/10.1016/j.cmet.2016.09.013Get rights and content
Under an Elsevier user license
open archive

Highlights

  • NMN suppresses age-associated body weight gain and enhances energy metabolism

  • NMN improves insulin sensitivity, eye function, and other features with no toxicity

  • NMN prevents age-associated gene expression changes in a tissue-specific manner

  • NMN is an effective anti-aging intervention that could be translated to humans

Summary

NAD+ availability decreases with age and in certain disease conditions. Nicotinamide mononucleotide (NMN), a key NAD+ intermediate, has been shown to enhance NAD+ biosynthesis and ameliorate various pathologies in mouse disease models. In this study, we conducted a 12-month-long NMN administration to regular chow-fed wild-type C57BL/6N mice during their normal aging. Orally administered NMN was quickly utilized to synthesize NAD+ in tissues. Remarkably, NMN effectively mitigates age-associated physiological decline in mice. Without any obvious toxicity or deleterious effects, NMN suppressed age-associated body weight gain, enhanced energy metabolism, promoted physical activity, improved insulin sensitivity and plasma lipid profile, and ameliorated eye function and other pathophysiologies. Consistent with these phenotypes, NMN prevented age-associated gene expression changes in key metabolic organs and enhanced mitochondrial oxidative metabolism and mitonuclear protein imbalance in skeletal muscle. These effects of NMN highlight the preventive and therapeutic potential of NAD+ intermediates as effective anti-aging interventions in humans.

Keywords

aging
nicotinamide mononucleotide
NMN
NAD+ precursor
NAD+
energy metabolism
glucose metabolism
insulin sensitivity
mitochondria
eye function
anti-aging

Cited by (0)

7

Present address: Gladstone Institute of Neurological Disease and Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA

8

Lead Contact